All In Biotech

Drug Trial Radar · NCT06660654

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

335

Planned (sponsor's estimate)

Start

Jan 6, 2025

Primary completion

Dec 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumors

Interventions

  • Raludotatug deruxtecanDrug

    IV administration Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)Time frame: Baseline up to 48 months
  2. Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)Time frame: Baseline up to 48 months
  3. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)Time frame: Baseline up to 48 months

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • Northside Hospital

    Marietta, Georgia

  • University of Michigan Comprehensive Cancer Center Michigan Medicine

    Ann Arbor, Michigan

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Women's Cancer Care Associates

    Albany, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Clinical Research Alliance

    Westbury, New York

  • West Cancer Center and Research Institute

    Germantown, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • UZ Leuven Gynaec onco

    Leuven, Belgium

  • ZAS Sint-Augustinus

    Wilrijk, Belgium

  • Hunan Cancer Hospital

    Changsha, China

  • Shanghai Cancer center

    Shanghai, China

  • Herlev og Gentofte Hosp

    Copenhagen, Denmark

  • François Baclesse Center

    Caen, France

  • Centre Georges-François Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Grp Hsp Diac Croix Saint Simon

    Paris, France

  • Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie

    Plérin, France

  • Ico - Site René Gauducheau

    Saint-Herblain, France

  • Institut Claudius Regaud

    Toulouse, France

  • Gustave Roussy

    Villejuif, France

  • AO per lEmergenza Cannizzaro

    Catania, Italy

  • Irccs Ospedale San Martino

    Genova, Italy

  • IRCCS Dino Amadori - IRST

    Meldola, Italy

  • IRCCS San Raffaele

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Federico II Hospital

    Naples, Italy

  • Azienda Ospedaliera S Maria

    Terni, Italy

  • Hyogo Cancer Center

    Akashi, Japan

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Japan

  • National Cancer Center Hospital East

    Kashiwa, Japan

  • The Cancer Institute Hospital of Jfcr

    Kōtoku, Japan

  • Aichi Cancer Centre

    Nagoya, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

  • National Cancer Center

    Goyang-si, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.